



Performance VS OMXS30



ExpreS2ion Biotech: Finalized terms of SEK53m rights issue

Redeye comments on ExpreS2ion's finalized rights issue of approximately SEK53m, including free-of-charge TO13 warrants, aimed at funding completion of the ES2B-C001 phase I program and supporting platform development. While the financing significantly strengthens the company's runway, the substantial dilution relative to our prior assumptions weighs heavy on our per share valuation.

Share Information

Share Price SEK	5.6
Number of shares (M)	3.5
Marketplace	First North Stockholm
CEO	Bent U. Frandsen
Chairman	Martin Roland Jensen

Key Stats

Market Cap	19.7m SEK
Entprs. Value (EV)	-27.7m SEK
Net Debt (2025Q4)	-47.5m SEK
30 Day Avg Vol	25 K
Dividend Yield	N/A

Top Holders

Name	Ownership
Johnnie Nicklas Lagard	1.7%
Avanza Pension	1.61%
Bjarke Krysel Christensen	1.47%
Danica Pension	1.46%
John Harling	1.45%
Mai-Britt Markmann	1.43%
Jacob Lorents Tingleff	1.23%
Benno Juul Nielsen	1.01%
John Laursen	0.97%
Lars Ebbeskov Abrahamsen	0.88%

ExpreS2ion has resolved on a fully pre-emptive rights issue of approximately SEK53m before transaction costs, in line with the previously announced intention. The subscription price is set at SEK1.60 per unit, where each unit consists of one new share and one warrant (TO13) issued free of charge. Existing shareholders receive 47 unit rights per share, with five rights required to subscribe for one unit. The subscription period runs from 16–30 April 2026, with a record date of 14 April. The subscription price corresponds to a ~20% discount to TERP, but relative to the previous day's closing price the effective discount is around 77%. The issue is covered to approximately 60% through subscription commitments from members of the company's board of directors and management (c.1.3%) and guarantee commitments (c.58.6%), with a guarantee compensation of 14%.

Rights issue: Actual vs. Estimates (SEKm)

EURm	Actual	Estimate	Diff (%)
Gross proceeds	53,1	70,0	-24%
Net proceeds	44,1	63,0	-30%
Subscription price (per share)	1,6	7,3	-78%
Discount (to yesterday's close)	77,1%	-3,7%	-2 173%
Discount to share price before rights issue announcement	89,5%	52,4%	71%
Shares outstanding post issue (m)	36,7	13,2	178%
Dilution	90,4%	73,2%	23%

*Assuming 100% subscription rate.

If fully subscribed, the company will receive gross proceeds of SEK53m with total transaction costs expected to be around SEK9m. The attached TO13 warrants, exercisable in September 2026 at 70% of the VWAP (floor SEK1.6), could provide an additional SEK53m at minimum pricing and potentially up to ~SEK100m depending on share price development. The structure follows a typical Nordic small-cap biotech financing but the final pricing came in significantly below our previous assumptions. Compared to our earlier estimates from before the initial announcement of the rights issue, the subscription price is materially lower (SEK1.6 vs SEK7.3 assumed), resulting in substantially higher dilution, with shares outstanding increasing to ~36.7m post issue versus our earlier estimate of ~13.2m.

Use of proceeds
 Redeye Equity Analysts

Kevin Sule
 kevin.sule@redeye.se

Richard Ramanius
 richard.ramanius@redeye.se

More research on ExpreS2ion
 Biotech Holding

Scan the QR code to access all Redeye publications and research tools regarding ExpreS2ion Biotech Holding.

redeye.se/company/expres2ion-biotech-holding

The Board states that existing working capital is insufficient to fund operations over the coming 12 months, making the financing necessary to continue execution of the business plan. The proceeds are primarily intended to advance the company's lead oncology program and maintain operational momentum across the platform. Allocation of net proceeds is expected as follows:

- ~55% to advance ES2B-C001 and complete phase I, including safety, dose-escalation, and immunogenicity readouts while supporting partnering discussions
- ~20% to strengthen shared R&D and manufacturing capabilities, including CMC and platform investments
- ~20% to grow the CRO/service business and increase recurring revenues
- ~5% to co-finance grant-funded pipeline programs

The timing aligns with the recent [phase I immunogenicity update](#) showing antibody titres increasing with repeated dosing and no safety concerns, which supports continued dose escalation to 450 µg. Securing funding at this stage reduces execution risk ahead of the key phase I inflection points expected in 2026. However, we believe that the raise should primarily be viewed as funding to complete phase I rather than financing a subsequent phase II study.

Valuation

The finalized terms are significantly more dilutive than our previous assumptions. At full subscription, dilution from the rights issue alone amounts to approximately 90%, and up to ~95% including full warrant exercise. This materially increases the share count and mechanically lowers our per-share valuation. The low subscription price and large number of new shares will likely continue to pressure

the share price in the near term, particularly as arbitrage trading around rights and warrants typically increases volatility.

Given the finalized terms, we provide a provisional valuation update. Incorporating the new structure and assuming 80% subscription rate and SEK1.6 subscription price in both the rights issue and subsequent TO13 warrants, our updated base case amounts to SEK7 per share. This reflects the increased dilution versus our previous model, partly offset by improved funding visibility through phase I completion and potential additional warrant proceeds. While the financing significantly strengthens the company's ability to reach key clinical milestones, the markedly lower pricing and expanded share base compared to our previous estimates mechanically reduces per-share upside in the near term. This shifts value creation toward successful phase I data and future partnering discussions, which remains the main potential catalysts ahead.

Valuation summary (SEKm) - Base case						
Program	Indication	Stage	Launch	Peak sales (\$m)	Probability (LoA)	Value, r-adj (SEKm)
ES2B-C001	HER2+ breast cancer	I	2033	2250	9%	285
Platform/CRO						75
AdaptVac (34% ownership)						72
Tech Value (SEKm)						433
Est. net cash						48
Shared costs						-160,9
Equity Value						319
Shares outstanding						3,5
Est. Increase in shares (from share issue & warrants)						59,7
Est. Increase in cash (from share issue & warrants)						108
WACC: 16%						Base case
						7,0

Disclaimer

Important Information

Redeye Sweden AB ("Redeye Nordic Growth" or "the Company") is a specialist financial advisory boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the technology and life science sectors. We provide services within corporate broking, equity research and investor relations. Our strengths are our award-winning research department, experienced advisers, a unique investor network, and the powerful distribution channel redeye.se.

The Redeye Group

Redeye Nordic Growth is part of a group of companies ("The Redeye Group") within the meaning of Article 2(11) of Directive 2013/34/EU (the Accounting Directive). The Redeye Group includes RedHold AB, Redeye AB, Redeye Sweden AB and Redeye Capital AB.

Regulatory Framework

This investment research is produced and disseminated in accordance with the European Union regulatory framework governing investment recommendations:

- Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), in particular Article 20 concerning investment recommendations and disclosure of interests and conflicts of interest.
- Commission Delegated Regulation (EU) 2016/958 supplementing MAR with regulatory technical standards for the objective presentation of investment recommendations and the disclosure of particular interests or indications of conflicts of interest.

Redeye Nordic Growth is an "expert" within the meaning of Article 1 of Delegated Regulation (EU) 2016/958, being a person referred to in Article 3(1)(34)(ii) of MAR who repeatedly proposes investment decisions in respect of financial instruments and presents itself as having financial expertise and experience. As such, Redeye Nordic Growth ensures that all research is objectively presented, that valuation methodologies and underlying assumptions are transparent, and that all relevant interests and conflicts of interest are disclosed in accordance with Articles 4 and 6(1) of Delegated Regulation (EU) 2016/958.

Objective Presentation of Recommendations

In compliance with Articles 3 and 4 of Delegated Regulation (EU) 2016/958, Redeye Nordic Growth ensures that all investment recommendations include:

- Clear identification of the persons responsible for producing the recommendation, including the name and job title of all natural persons involved.
 - A clear distinction between factual information and interpretations, estimates, opinions, and other non-factual information.
 - Reliable sources for all material information, with any doubts as to reliability clearly indicated.
 - A summary of the valuation basis, methodology, and underlying assumptions used to evaluate the financial instrument or issuer, or to set a price target, as well as an indication of any material changes thereto.
 - An indication of where detailed information about the valuation or methodology and underlying assumptions is directly and easily accessible.
 - An explanation of the meaning of each recommendation category used (e.g., Buy, Hold, Sell), including the relevant time horizon and appropriate risk warnings.
 - The date and time of completion of the recommendation and any prices of financial instruments mentioned therein.
 - A 12-month track record of all recommendations disseminated on the relevant financial instrument or issuer, including for each: the date of dissemination, analyst identity, price target, relevant market price at the time of dissemination, direction of the recommendation, and validity period.
 - Where the recommendation has been disclosed to the issuer and subsequently amended, a statement to that effect.
-

Conflicts of Interest

Redeye Nordic Growth's research department is regulated by operational and administrative rules established to avoid conflicts of interest and to ensure the objectivity and independence of its analysts. Disclosures may be made either in this document, or on Redeye.se. In accordance with Articles 5 and 6(1) of Delegated Regulation (EU) 2016/958, the following disclosures and measures apply:

Disclosures

- Redeye Nordic Growth discloses any net long or short position exceeding 0.5% of the total issued share capital of any issuer covered in its research, calculated in accordance with Article 3 of Regulation (EU) No 236/2012 and Chapters III and IV of Delegated Regulation (EU) No 918/2012, specifying whether the position is long or short.
- Redeye Nordic Growth discloses if the issuer holds more than 5% of Redeye Nordic Growth's total issued share capital.
- Redeye Nordic Growth discloses any other significant financial interests concerning the issuer.
- Redeye Nordic Growth discloses whether the recommendation was shown to the issuer prior to dissemination and subsequently altered.
- Redeye Nordic Growth discloses the existence of any agreement with the issuer relating to the production of the recommendation.

Group Disclosures

In accordance with Article 6(1)(c) of Delegated Regulation (EU) 2016/958, Redeye Nordic Growth also discloses relevant interests and relationships held by any other company within The Redeye Group. This includes disclosure of whether Redeye Nordic Growth or any company within The Redeye Group:

- Is a market maker or liquidity provider in the financial instruments of the issuer.
- Has been lead manager or co-lead manager over the previous 12 months of any publicly disclosed offer of financial instruments of the issuer.
- Is party to an agreement with the issuer relating to the provision of investment services within the meaning of Sections A and B of Annex I to Directive 2014/65/EU (MiFID II), provided such disclosure does not entail revealing confidential commercial information and the agreement has been in effect over the previous 12 months or has given rise during the same period to an obligation to pay or receive compensation.

Internal Measures

- Employees of Redeye Nordic Growth are prohibited from trading in financial instruments of companies subject to the Company's research analysis, from the date Redeye Nordic Growth publishes its analysis until one trading day thereafter.
- Redeye Nordic Growth has established internal arrangements designed to prevent and manage conflicts of interest with respect to its investment recommendations.
- The Redeye Group has established arrangements to identify, prevent and manage conflicts of interest that may arise between companies within The Redeye Group, including conflicts between the production of investment recommendations and the provision of investment services by other group companies.

Remuneration

Readers of these reports should assume that Redeye Nordic Growth or other companies within The Redeye Group may have received or will receive remuneration from the company/companies cited in the report for the performance of financial advisory services or other investment services. Such remuneration is of a predetermined amount and is not dependent on the content of the research. Where such an agreement exists, it is disclosed in the individual research report.

Limitation of Liability

This document was prepared for information purposes for general distribution and is not intended to be advisory. The information contained in this research is based on sources deemed reliable by Redeye Nordic Growth. However, Redeye Nordic Growth cannot guarantee the accuracy of the information. The forward-looking information in the research is based on subjective assessments about the future, which constitutes a factor of uncertainty. Redeye Nordic Growth cannot guarantee that forecasts and forward-looking statements will materialize. Investors shall conduct all investment decisions independently. This research is intended to be one of a number of tools that can be used in making an investment decision. All investors are therefore encouraged to supplement this information with additional relevant data and to consult a financial advisor prior to an investment decision. Accordingly, Redeye Nordic Growth accepts no liability for any loss or damage resulting from the use of this research.

Recommendation History

In accordance with Article 4(1)(i) of Delegated Regulation (EU) 2016/958, a complete list of all recommendations disseminated by Redeye Nordic Growth on the relevant financial instrument or issuer during the preceding 12-month period is available upon request and at redeye.se.

Redeye Nordic Growth's research coverage

Redeye Nordic Growth's research analyses consist of case-based analyses, which imply that the frequency of the analytical reports may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Recommendation structure

Redeye Nordic Growth does not issue any investment recommendations for fundamental analysis. However, Redeye Nordic Growth has developed a proprietary analysis and rating model, Redeye Rating, in which each company is analysed and evaluated. This analysis aims to provide an independent assessment of the company in question, its opportunities, risks, etc. The purpose is to provide an objective and professional set of data for owners and investors to use in their decision-making.

Duplication and distribution

This document may not be duplicated, reproduced or copied for purposes other than personal use. The document may not be distributed to physical or legal entities that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.